We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+9.58%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$155M
AUM Growth
+$7.79M
Cap. Flow
-$3.04M
Cap. Flow %
-1.96%
Top 10 Hldgs %
83.08%
Holding
58
New
5
Increased
5
Reduced
13
Closed
4

Top Buys

Rank Stock Value
1
DOVA
Dova Pharmaceuticals, Inc. Common Stock
DOVA
+$714K
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$568K
3
OPK icon
Opko Health
OPK
+$552K
4
ARVN icon
Arvinas
ARVN
+$494K
5
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$408K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$1.41M
2
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$815K
3
CFRX
ContraFect Corporation
CFRX
+$576K
4
VCYT icon
Veracyte
VCYT
+$551K
5
OVV icon
Ovintiv
OVV
+$441K

Sector Composition

Rank Sector Weight
1 Healthcare 96.81%
2 Energy 2.32%
3 Consumer Staples 0.25%
4 Industrials 0.16%
5 Consumer Discretionary 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMRN
26
Amarin Corp
AMRN
$286M
$651K 0.42%
+2,000
New +$151K
DOVA
27
DELISTED
Dova Pharmaceuticals, Inc. Common Stock
DOVA
$629K 0.41%
+30,000
New +$714K
VYGR icon
28
Voyager Therapeutics
VYGR
$187M
$624K 0.4%
33,000
– –
NKTR icon
29
Nektar Therapeutics
NKTR
$2.21B
$579K 0.37%
633
– –
IFRX icon
30
InflaRx
IFRX
$271M
$549K 0.35%
16,000
– –
ICPT
31
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$543K 0.35%
4,300
– –
PXD
32
DELISTED
Pioneer Natural Resource Co.
PXD
$523K 0.34%
3,000
– –
ARVN icon
33
Arvinas
ARVN
$517M
$506K 0.33%
+30,000
New +$494K
HROW icon
34
Harrow
HROW
$1.68B
$500K 0.32%
180,000
– –
XNCR icon
35
Xencor
XNCR
$1.4B
$479K 0.31%
12,300
– –
VCYT icon
36
Veracyte
VCYT
$4.66B
$466K 0.3%
48,767
-50,000
-51% -$551K
MYGN icon
37
Myriad Genetics
MYGN
$560M
$460K 0.3%
10,000
– –
FOLD
38
DELISTED
Amicus Therapeutics
FOLD
$459K 0.3%
38,000
+4,000
+12% +$55.9K
AVEO
39
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$397K 0.26%
12,000
+2,000
+20% +$51.4K
YTEN
40
DELISTED
Yield10 Bioscience, Inc. Common Stock
YTEN
$390K 0.25%
282
– –
ODT
41
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$388K 0.25%
+20,000
New +$408K
AXGN icon
42
Axogen
AXGN
$2.1B
$369K 0.24%
10,000
-2,000
-17% -$87.3K
OPK icon
43
Opko Health
OPK
$906M
$360K 0.23%
+103,956
New +$552K
TSRO
44
DELISTED
TESARO, Inc.
TSRO
$320K 0.21%
8,200
– –
SLDB icon
45
Solid Biosciences
SLDB
$843M
$283K 0.18%
400
– –
OMED
46
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
$252K 0.16%
118,689
+20,000
+20% +$47.9K
SITO
47
DELISTED
SITO MOBILE, LTD
SITO
$249K 0.16%
140,000
– –
ECYT
48
DELISTED
Endocyte, Inc. Common Stock
ECYT
$249K 0.16%
14,000
+4,000
+40% +$68.7K
GNMX
49
DELISTED
Aevi Genomic Medicine Inc
GNMX
$157K 0.1%
128,000
– –
GNCA
50
DELISTED
Genocea Biosciences, Inc.
GNCA
$147K 0.09%
23,625
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Birchview Capital held 58 positions worth $155M, up 5.3% from $147M the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Birchview Capital's Q3 2018 filing shows 5 new, 5 increased, 13 reduced and 4 closed positions. Its largest new stake was Dova Pharmaceuticals, Inc. Common Stock: 30,000 shares worth $629K. The largest sale was Celgene Corp, an estimated $1.41M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Energy and Consumer Staples.

  • Birchview Capital's largest Q3 2018 buy was Dova Pharmaceuticals, Inc. Common Stock: 30,000 shares worth $629K.
  • Birchview Capital added most to Clementia Pharmaceuticals Inc. in Q3 2018, an estimated $568K increase.
  • Birchview Capital's biggest Q3 2018 reduction was Celgene Corp, cutting an estimated $1.41M.
  • Birchview Capital fully exited Aptinyx Inc. Common Stock in Q3 2018, selling an estimated $242K.
  • Birchview Capital's ten largest holdings make up 83% of its $155M portfolio in Q3 2018.
  • Birchview Capital opened 5 new positions and closed 4 in Q3 2018.
  • Birchview Capital's portfolio value rose 5.3% quarter-over-quarter to $155M.

Based on Birchview Capital's 13F filing for Q3 2018, filed 1 Nov 2018.